Archer Aviation Inc vs Smith & Nephew plc — how do they compare? Archer Aviation Inc trades at $6.3 (market cap $5.23B), while Smith & Nephew plc trades at $29.77 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 2.4× Archer Aviation Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.
| ACHR | SNN | |
|---|---|---|
Market Cap | $5.23B | $12.54B |
Sector | Industrials | Health |
52-Week High | $13.64 | $38.70 |
52-Week Low | $4.44 | $28.73 |
Enterprise Value | $3.79B | $15.57B |
Dividend Yield | — | 2.65% |
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $6.41, up 2.4% today, with a bullish technical signal from moving averages. The stock shows strong analyst support (78% buy ratings) amid recent news of a strategic Boeing deal to acquire three businesses, boosting its defense and AI aviation portfolio. However, fundamentals remain weak with a P/S ratio of 719.85 and deeply negative profit margins, as the company is pre-revenue and burning cash to develop its eVTOL technology.
Outlook hinges on successful commercialization of air taxis and integration of Boeing assets, offering growth potential but carrying high execution risk. Investors face substantial losses until revenue scales, with net income margin at -11,590% in 2026. The Boeing partnership provides a cash flow bridge via defense revenue, yet dilution from equity offerings and regulatory delays pose near-term headwinds.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Trailing returns across standard periods
Latest headlines on both assets
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →